[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"apparent-resistant-hypertension\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:apparent-resistant-hypertension":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100612911","rapid-management-of-resistant-hypertension-in-the-public-health-system-fast-control-100612911",false,"NCT07259733","Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)","Strategy for Rapid Control of Apparent Resistant Arterial Hypertension in the Public Health System (FAST Control)","FastControl","Inclusion Criteria: Age between 18 and 75 years;\n\nTreatment with 3 to 5 classes of antihypertensive drugs, including a maximum dose of an ACE inhibitor or ARB, a thiazide or thiazide-like diuretic, and a calcium channel blocker (CCB);\n\nRecent 24-hour ambulatory blood pressure monitoring (ABPM) (\\\u003C1 month) showing values above target (24-hour BP ≥130\u002F80 mmHg);\n\nOffice blood pressure ≥140\u002F90 mmHg;\n\nPoor adherence to treatment, defined as a score ≥1 point on the Morisky Medication Adherence Scale (MMAS-4).\n\n\\-\n\nExclusion Criteria:Secondary hypertension (including hyperaldosteronism, pheochromocytoma, or renovascular hypertension);\n\nHistory of intolerance or adverse reactions to study medications, such as ACE inhibitors (cough or angioedema), thiazide or thiazide-like diuretics (electrolyte disturbances), or calcium channel blockers (significant ankle edema or headache);\n\nIndispensable use of beta-blockers or mineralocorticoid receptor antagonists;\n\nOffice blood pressure ≥ 220 × 120 mmHg;\n\nReduced left ventricular ejection fraction (LVEF \\\u003C 55%);\n\nSevere renal impairment (creatinine clearance \\\u003C 30 mL\u002Fmin or eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²);\n\nAtrial fibrillation or atrial flutter;\n\nUse of oral anticoagulants;\n\nSignificant valvular heart disease;\n\nBody mass index (BMI) ≥ 40 kg\u002Fm²;\n\nPregnant or breastfeeding women;\n\nSevere psychiatric disorders;\n\nActive malignancy with life expectancy \\\u003C 2 years;\n\n\\-","ALL","18 Years","75 Years",{"count":21,"type":22},142,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a single-center, open-label, randomized clinical trial conducted at the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. The study evaluates a simplified treatment strategy for patients with apparent resistant hypertension, comparing fixed triple combination therapy (perindopril, indapamide, and amlodipine) with usual care using multiple separate antihypertensive drugs. The primary objective is to compare 24-hour blood pressure control as measured by ABPM at 12 weeks between the two treatment strategies. Enrollment began on July 15, 2023, and this study was registered retrospectively.",[28,29,30],"Apparent Resistant Hypertension","Hypertension","High Blood Pressure",[32],"Apparent resistant hypertension; Fixed-dose combination; Triple combination therapy; Perindoprile; Indapamide; Amlodipine; Clinical Trial; Brazil","RECRUITING","2025-11-21",{"date":36,"type":37},"2025-12-02","ACTUAL",{"date":39,"type":37},"2023-07-15",{"date":41,"type":22},"2026-12-31",{"name":43,"class":44},"Instituto Dante Pazzanese de Cardiologia","OTHER"]